Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model
Research article published in Coronary artery disease (1996)
Abstract
OBJECTIVE: To compare the efficacy of Yagin, a factor Xa inhibitor derived from the leech Hirudo medicinalis, with those of heparin and hirudin as adjuncts to recombinant tissue-type plasminogen activator (rTPA) thrombolysis in a rabbit thrombosis model. METHODS: Thirty-one animals were allocated randomly to three groups, all administered four boluses of 0.25 mg/kg rTPA every 10 min for 30 min, 17 mg/kg aspirin intravenously, and heparin (as a 100 IU/kg bolus followed by infusion of 50 IU/kg heparin per h), hirudin (as a 2 mg/kg bolus followed by infusion of 1 mg/kg hirudin per h), or Yagin (as an 80 micrograms/kg bolus followed by infusion of 43 micrograms/kg Yagin per h). RESULTS: Administration of Yagin was associated with a significant acceleration of the reflow time, this time being 14.5 +/- 1.2 min with Yagin, 25.8 +/- 5.2 min with heparin (P < 0.0001, versus Yagin), and 28.7 +/- 16.0 min with hirudin (P = 0.012, versus Yagin). Overall patency did not differ significantly among the three groups. CONCLUSIONS: At the indicated single doses, inhibition of factor Xa by a relatively low concentration of Yagin was found to be superior than that with either heparin or hirudin for accelerating rTPA thrombolysis.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
To compare the efficacy of Yagin, a factor Xa inhibitor derived from the leech Hirudo medicinalis, with those of heparin and hirudin as adjuncts to recombinant tissue-type plasminogen activator (rTPA) thrombolysis in a rabbit thrombosis model.
Por qué esto importa para la hirudoterapia
Este estudio comparó la eficacia de Yagin, un inhibidor del factor Xa derivado de la sanguijuela Hirudo medicinalis, frente a heparina e hirudina como coadyuvantes de la trombólisis con activador tisular del plasminógeno recombinante (rTPA) en un modelo de trombosis en conejo con 31 animales. Yagin aceleró significativamente el tiempo de reperfusión (14.5 ± 1.2 min) en comparación tanto con heparina (25.8 ± 5.2 min, P < 0.0001) como con hirudina (28.7 ± 16.0 min, P = 0.012), aunque la permeabilidad general no difirió significativamente entre los tres grupos. Esto es directamente relevante para el ámbito de ASH, ya que caracteriza un anticoagulante bioactivo de la sanguijuela medicinal y compara directamente su eficacia como coadyuvante trombolítico frente a la hirudina in vivo. No obstante, el estudio se limita a un modelo animal con dosis únicas y un tamaño muestral modesto, y la relevancia clínica no está demostrada.
Citación
Enhancement of recombinant tissue-type plasminogen activator thrombolysis with a selective factor Xa inhibitor derived from the leech Hirudo medicinalis: comparison with heparin and hirudin in a rabbit thrombosis model
Kornowski R et al. · Coronary artery disease, 1996
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026